Published in Nature on December 10, 2008
Diverse somatic mutation patterns and pathway alterations in human cancers. Nature (2010) 10.83
Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science (2010) 10.78
Mutations in GNA11 in uveal melanoma. N Engl J Med (2010) 7.52
Frequent mutation of BAP1 in metastasizing uveal melanomas. Science (2010) 7.47
The Hippo pathway and human cancer. Nat Rev Cancer (2013) 5.17
The Hippo pathway: regulators and regulations. Genes Dev (2013) 4.55
Sturge-Weber syndrome and port-wine stains caused by somatic mutation in GNAQ. N Engl J Med (2013) 4.26
Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncol (2012) 4.19
Germline mutations in BAP1 predispose to melanocytic tumors. Nat Genet (2011) 3.91
Oncogenic mutations in GNAQ occur early in uveal melanoma. Invest Ophthalmol Vis Sci (2008) 3.14
Melanoma: from mutations to medicine. Genes Dev (2012) 2.59
Emerging patterns of somatic mutations in cancer. Nat Rev Genet (2013) 2.50
Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial. JAMA (2014) 2.48
From genes to drugs: targeted strategies for melanoma. Nat Rev Cancer (2012) 2.46
Hippo Pathway in Organ Size Control, Tissue Homeostasis, and Cancer. Cell (2015) 2.31
Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials. PLoS One (2012) 2.21
Recurrent mutations at codon 625 of the splicing factor SF3B1 in uveal melanoma. Nat Genet (2013) 2.20
Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. J Clin Oncol (2013) 2.11
Mutations affecting G-protein subunit α11 in hypercalcemia and hypocalcemia. N Engl J Med (2013) 2.05
The emerging mutational landscape of G proteins and G-protein-coupled receptors in cancer. Nat Rev Cancer (2013) 2.05
Exome sequencing identifies recurrent somatic mutations in EIF1AX and SF3B1 in uveal melanoma with disomy 3. Nat Genet (2013) 2.05
Regulators of G-protein signaling and their Gα substrates: promises and challenges in their use as drug discovery targets. Pharmacol Rev (2011) 1.98
Integrative genome comparison of primary and metastatic melanomas. PLoS One (2010) 1.97
Hippo-independent activation of YAP by the GNAQ uveal melanoma oncogene through a trio-regulated rho GTPase signaling circuitry. Cancer Cell (2014) 1.96
Oncogenic GNAQ mutations are not correlated with disease-free survival in uveal melanoma. Br J Cancer (2009) 1.93
Pasteurella multocida toxin activation of heterotrimeric G proteins by deamidation. Proc Natl Acad Sci U S A (2009) 1.88
Ambiguous melanocytic tumors with loss of 3p21. Am J Surg Pathol (2014) 1.83
The melanomas: a synthesis of epidemiological, clinical, histopathological, genetic, and biological aspects, supporting distinct subtypes, causal pathways, and cells of origin. Pigment Cell Melanoma Res (2011) 1.81
Oncogene mutation profiling of pediatric solid tumors reveals significant subsets of embryonal rhabdomyosarcoma and neuroblastoma with mutated genes in growth signaling pathways. Clin Cancer Res (2011) 1.80
Mutant Gq/11 promote uveal melanoma tumorigenesis by activating YAP. Cancer Cell (2014) 1.79
Kinetic scaffolding mediated by a phospholipase C-beta and Gq signaling complex. Science (2010) 1.78
The role of miR-18b in MDM2-p53 pathway signaling and melanoma progression. J Natl Cancer Inst (2013) 1.76
Primary melanoma of the CNS in children is driven by congenital expression of oncogenic NRAS in melanocytes. Cancer Discov (2013) 1.71
SF3B1 mutations are associated with alternative splicing in uveal melanoma. Cancer Discov (2013) 1.68
Activating mutations of the GNAQ gene: a frequent event in primary melanocytic neoplasms of the central nervous system. Acta Neuropathol (2010) 1.65
Whole-genome sequencing reveals complex mechanisms of intrinsic resistance to BRAF inhibition. Ann Oncol (2014) 1.64
Primary mucosal melanomas: a comprehensive review. Int J Clin Exp Pathol (2012) 1.64
Mutational profile of GNAQQ209 in human tumors. PLoS One (2009) 1.62
A distinct subset of atypical Spitz tumors is characterized by BRAF mutation and loss of BAP1 expression. Am J Surg Pathol (2012) 1.57
Recurrent BRAF kinase fusions in melanocytic tumors offer an opportunity for targeted therapy. Pigment Cell Melanoma Res (2013) 1.56
Melanoma: new insights and new therapies. J Invest Dermatol (2012) 1.54
Multiplex mutation screening by mass spectrometry evaluation of 820 cases from a personalized cancer medicine registry. J Mol Diagn (2011) 1.53
Combination small molecule MEK and PI3K inhibition enhances uveal melanoma cell death in a mutant GNAQ- and GNA11-dependent manner. Clin Cancer Res (2012) 1.52
Structural basis for the specific inhibition of heterotrimeric Gq protein by a small molecule. Proc Natl Acad Sci U S A (2010) 1.49
Genetic and morphologic features for melanoma classification. Pigment Cell Melanoma Res (2010) 1.47
Mutations in G protein β subunits promote transformation and kinase inhibitor resistance. Nat Med (2014) 1.46
Ocular melanoma: an overview of the current status. Int J Clin Exp Pathol (2013) 1.43
Mutation-driven drug development in melanoma. Curr Opin Oncol (2010) 1.43
A genome-wide RNAi screen reveals a Trio-regulated Rho GTPase circuitry transducing mitogenic signals initiated by G protein-coupled receptors. Mol Cell (2012) 1.40
Whole-genome landscapes of major melanoma subtypes. Nature (2017) 1.40
The genetics of uveal melanoma: an emerging framework for targeted therapy. Pigment Cell Melanoma Res (2012) 1.39
Isolated hepatic perfusion as a treatment for uveal melanoma liver metastases (the SCANDIUM trial): study protocol for a randomized controlled trial. Trials (2014) 1.39
TERT promoter mutations in ocular melanoma distinguish between conjunctival and uveal tumours. Br J Cancer (2013) 1.38
The melanoma revolution: from UV carcinogenesis to a new era in therapeutics. Science (2014) 1.37
Analysis of the genome to personalize therapy for melanoma. Oncogene (2010) 1.33
A role for ATF2 in regulating MITF and melanoma development. PLoS Genet (2010) 1.28
Metastatic uveal melanoma: biology and emerging treatments. Cancer J (2012) 1.27
Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations. Oncogene (2013) 1.25
Genetic and molecular characterization of uveal melanoma cell lines. Pigment Cell Melanoma Res (2012) 1.23
The molecular pathology of melanoma: an integrated taxonomy of melanocytic neoplasia. Annu Rev Pathol (2014) 1.22
A meta-analysis of somatic mutations from next generation sequencing of 241 melanomas: a road map for the study of genes with potential clinical relevance. Mol Cancer Ther (2014) 1.21
Genetic risk factors for melanoma. Hum Genet (2009) 1.21
Identification of unique MEK-dependent genes in GNAQ mutant uveal melanoma involved in cell growth, tumor cell invasion, and MEK resistance. Clin Cancer Res (2012) 1.20
Expression of GIV/Girdin, a metastasis-related protein, predicts patient survival in colon cancer. FASEB J (2010) 1.19
Dormancy of metastatic melanoma. Pigment Cell Melanoma Res (2009) 1.19
Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines. Mol Cancer (2012) 1.18
Pathways and therapeutic targets in melanoma. Oncotarget (2014) 1.17
Dabrafenib and its potential for the treatment of metastatic melanoma. Drug Des Devel Ther (2012) 1.16
A melanoma molecular disease model. PLoS One (2011) 1.15
Recent developments in prognostic and predictive testing in uveal melanoma. Curr Opin Ophthalmol (2014) 1.13
Improved discrimination of melanotic schwannoma from melanocytic lesions by combined morphological and GNAQ mutational analysis. Acta Neuropathol (2010) 1.11
Patient-derived xenografts recapitulate molecular features of human uveal melanomas. Mol Oncol (2013) 1.11
The intersection of immune-directed and molecularly targeted therapy in advanced melanoma: where we have been, are, and will be. Clin Cancer Res (2013) 1.10
Network-guided analysis of genes with altered somatic copy number and gene expression reveals pathways commonly perturbed in metastatic melanoma. PLoS One (2011) 1.09
The protein kinase C inhibitor enzastaurin exhibits antitumor activity against uveal melanoma. PLoS One (2012) 1.09
Genotype-dependent sensitivity of uveal melanoma cell lines to inhibition of B-Raf, MEK, and Akt kinases: rationale for personalized therapy. Invest Ophthalmol Vis Sci (2011) 1.07
Role of microRNA-182 in posterior uveal melanoma: regulation of tumor development through MITF, BCL2 and cyclin D2. PLoS One (2012) 1.07
The somatic GNAQ mutation c.548G>A (p.R183Q) is consistently found in Sturge-Weber syndrome. J Hum Genet (2014) 1.05
Contribution of CDKN2A/P16 ( INK4A ), P14 (ARF), CDK4 and BRCA1/2 germline mutations in individuals with suspected genetic predisposition to uveal melanoma. Fam Cancer (2010) 1.03
Roles of endothelin signaling in melanocyte development and melanoma. Pigment Cell Melanoma Res (2010) 1.03
Impact of combined mTOR and MEK inhibition in uveal melanoma is driven by tumor genotype. PLoS One (2012) 1.03
Protein kinase C inhibitor AEB071 targets ocular melanoma harboring GNAQ mutations via effects on the PKC/Erk1/2 and PKC/NF-κB pathways. Mol Cancer Ther (2012) 1.03
Beyond histology: translating tumor genotypes into clinically effective targeted therapies. Clin Cancer Res (2014) 1.01
New strategies in melanoma: molecular testing in advanced disease. Clin Cancer Res (2012) 1.01
Phase II DeCOG-study of ipilimumab in pretreated and treatment-naïve patients with metastatic uveal melanoma. PLoS One (2015) 1.01
GNAQ and GNA11 mutations in melanocytomas of the central nervous system. Acta Neuropathol (2012) 1.00
Lack of SF3B1 R625 mutations in cutaneous melanoma. Diagn Pathol (2013) 1.00
Molecular basis of a novel oncogenic mutation in GNAO1. Oncogene (2011) 1.00
Mosaic Activating Mutations in GNA11 and GNAQ Are Associated with Phakomatosis Pigmentovascularis and Extensive Dermal Melanocytosis. J Invest Dermatol (2016) 0.99
Uncommon GNAQ, MMP8, AKT3, EGFR, and PIK3R1 mutations in thyroid cancers. Endocr Pathol (2011) 0.99
Delving into somatic variation in sporadic melanoma. Pigment Cell Melanoma Res (2012) 0.99
Targeted therapy and immunotherapy in advanced melanoma: an evolving paradigm. Ther Adv Med Oncol (2013) 0.99
Biology of advanced uveal melanoma and next steps for clinical therapeutics. Pigment Cell Melanoma Res (2014) 0.99
Uveal melanoma. J Skin Cancer (2011) 0.98
Deep sequencing of uveal melanoma identifies a recurrent mutation in PLCB4. Oncotarget (2016) 0.98
Influence of immune privilege on ocular tumor development. Ocul Immunol Inflamm (2010) 0.97
Molecular nevogenesis. Dermatol Res Pract (2011) 0.97
Full-length Gα(q)-phospholipase C-β3 structure reveals interfaces of the C-terminal coiled-coil domain. Nat Struct Mol Biol (2013) 0.96
A growing family: adding mutated Erbb4 as a novel cancer target. Cell Cycle (2010) 0.95
Mutations of the BRAF gene in human cancer. Nature (2002) 65.42
Distinct sets of genetic alterations in melanoma. N Engl J Med (2005) 17.26
Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature (2005) 15.28
High frequency of BRAF mutations in nevi. Nat Genet (2002) 9.95
GTPase inhibiting mutations activate the alpha chain of Gs and stimulate adenylyl cyclase in human pituitary tumours. Nature (1989) 5.03
Two G protein oncogenes in human endocrine tumors. Science (1990) 4.46
A line of non-tumorigenic mouse melanocytes, syngeneic with the B16 melanoma and requiring a tumour promoter for growth. Int J Cancer (1987) 3.80
Protein kinase C is differentially stimulated by Wnt and Frizzled homologs in a G-protein-dependent manner. Curr Biol (1999) 3.25
The Wnt5A/protein kinase C pathway mediates motility in melanoma cells via the inhibition of metastasis suppressors and initiation of an epithelial to mesenchymal transition. J Biol Chem (2007) 3.24
Effects of G-protein mutations on skin color. Nat Genet (2004) 3.08
The temporal requirement for endothelin receptor-B signalling during neural crest development. Nature (1999) 2.42
Cell signalling diversity of the Gqalpha family of heterotrimeric G proteins. Cell Signal (2005) 2.32
Uveal melanoma: epidemiologic aspects. Ophthalmol Clin North Am (2005) 2.24
Activation of the MAPK pathway is a common event in uveal melanomas although it rarely occurs through mutation of BRAF or RAS. Br J Cancer (2005) 2.13
Separate GTP binding and GTPase activating domains of a G alpha subunit. Science (1993) 2.08
Dermal dendritic melanocytic proliferations: an update. Histopathology (2004) 1.84
Mutated alpha subunit of the Gq protein induces malignant transformation in NIH 3T3 cells. Mol Cell Biol (1992) 1.80
High BRAF mutation frequency does not characterize all melanocytic tumor types. Int J Cancer (2004) 1.79
Lifetime prevalence of uveal melanoma in white patients with oculo(dermal) melanocytosis. Ophthalmology (1998) 1.67
Stimulation of oncogenic metabotropic glutamate receptor 1 in melanoma cells activates ERK1/2 via PKCepsilon. Cell Signal (2005) 1.50
Dormant melanocytes in the dermis: do dermal melanocytes of acquired dermal melanocytosis exist from birth? Br J Dermatol (1998) 1.47
Cytogenetic analysis of uveal melanoma. Consistent occurrence of monosomy 3 and trisomy 8q. Cancer (1993) 1.40
Worldwide human relationships inferred from genome-wide patterns of variation. Science (2008) 22.44
Distinct sets of genetic alterations in melanoma. N Engl J Med (2005) 17.26
Signals of recent positive selection in a worldwide sample of human populations. Genome Res (2009) 8.38
Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol (2006) 7.76
Mutations in GNA11 in uveal melanoma. N Engl J Med (2010) 7.52
Reduction of macrophage infiltration and chemoattractant gene expression changes in white adipose tissue of morbidly obese subjects after surgery-induced weight loss. Diabetes (2005) 5.68
T-helper-1-cell cytokines drive cancer into senescence. Nature (2013) 4.47
Agouti-related peptide-expressing neurons are mandatory for feeding. Nat Neurosci (2005) 4.44
In melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signaling. Cancer Res (2006) 4.29
The Genetic Evolution of Melanoma from Precursor Lesions. N Engl J Med (2015) 4.24
Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. Hum Mol Genet (2003) 4.07
Ribosomal mutations cause p53-mediated dark skin and pleiotropic effects. Nat Genet (2008) 4.02
Germline mutations in BAP1 predispose to melanocytic tumors. Nat Genet (2011) 3.91
Molecular and evolutionary history of melanism in North American gray wolves. Science (2009) 3.87
Insulin action in AgRP-expressing neurons is required for suppression of hepatic glucose production. Cell Metab (2007) 3.69
Determinants of BRAF mutations in primary melanomas. J Natl Cancer Inst (2003) 3.65
KIT as a therapeutic target in metastatic melanoma. JAMA (2011) 3.49
A -defensin mutation causes black coat color in domestic dogs. Science (2007) 3.47
PI3K integrates the action of insulin and leptin on hypothalamic neurons. J Clin Invest (2005) 3.34
AMPK is essential for energy homeostasis regulation and glucose sensing by POMC and AgRP neurons. J Clin Invest (2007) 3.32
Forkhead protein FoxO1 mediates Agrp-dependent effects of leptin on food intake. Nat Med (2006) 3.24
Effects of G-protein mutations on skin color. Nat Genet (2004) 3.08
Collective and individual functions of leptin receptor modulated neurons controlling metabolism and ingestion. Endocrinology (2007) 2.95
MC1R germline variants confer risk for BRAF-mutant melanoma. Science (2006) 2.84
Weight loss regulates inflammation-related genes in white adipose tissue of obese subjects. FASEB J (2004) 2.82
Histopathological diagnostics of malignant melanoma in accordance with the recent AJCC classification 2009: Review of the literature and recommendations for general practice. J Dtsch Dermatol Ges (2011) 2.82
The mammalian gene function resource: the International Knockout Mouse Consortium. Mamm Genome (2012) 2.65
Anti-oncogenic role of the endoplasmic reticulum differentially activated by mutations in the MAPK pathway. Nat Cell Biol (2006) 2.58
Improving melanoma classification by integrating genetic and morphologic features. PLoS Med (2008) 2.52
Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B(high) cells. Cancer Cell (2013) 2.43
The role of insulin receptor substrate 2 in hypothalamic and beta cell function. J Clin Invest (2005) 2.40
A mouse atlas of gene expression: large-scale digital gene-expression profiles from precisely defined developing C57BL/6J mouse tissues and cells. Proc Natl Acad Sci U S A (2005) 2.35
Primary results of the Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT). A multicenter study of B-type natriuretic peptide levels, emergency department decision making, and outcomes in patients presenting with shortness of breath. J Am Coll Cardiol (2004) 2.27
Frequent mutations in the MITF pathway in melanoma. Pigment Cell Melanoma Res (2009) 2.27
Survival after intratumoral interleukin-2 treatment of 72 melanoma patients and response upon the first chemotherapy during follow-up. Cancer Immunol Immunother (2010) 2.18
Is the energy homeostasis system inherently biased toward weight gain? Diabetes (2003) 2.14
Effects of hypothalamic neurodegeneration on energy balance. PLoS Biol (2005) 2.11
Fifteen-year single center experience with the "Giessen Hybrid" approach for hypoplastic left heart and variants: current strategies and outcomes. Pediatr Cardiol (2014) 2.08
Congenital melanocytic nevi frequently harbor NRAS mutations but no BRAF mutations. J Invest Dermatol (2006) 2.04
Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation. Pigment Cell Melanoma Res (2008) 1.98
Beta-catenin induces immortalization of melanocytes by suppressing p16INK4a expression and cooperates with N-Ras in melanoma development. Genes Dev (2007) 1.98
Outcome in psychogenic nonepileptic seizures: 1 to 10-year follow-up in 164 patients. Ann Neurol (2003) 1.93
Immunology: hepatitis A virus link to atopic disease. Nature (2003) 1.88
Fluorescence in situ hybridization (FISH) as an ancillary diagnostic tool in the diagnosis of melanoma. Am J Surg Pathol (2009) 1.87
A regulatory toolbox of MiniPromoters to drive selective expression in the brain. Proc Natl Acad Sci U S A (2010) 1.85
Ambiguous melanocytic tumors with loss of 3p21. Am J Surg Pathol (2014) 1.83
The melanomas: a synthesis of epidemiological, clinical, histopathological, genetic, and biological aspects, supporting distinct subtypes, causal pathways, and cells of origin. Pigment Cell Melanoma Res (2011) 1.81
Cyclin D1 is a candidate oncogene in cutaneous melanoma. Cancer Res (2002) 1.78
Frequent p16-independent inactivation of p14ARF in human melanoma. J Natl Cancer Inst (2008) 1.78
A minority of foci or pan-nuclear apoptotic staining of gammaH2AX in the S phase after UV damage contain DNA double-strand breaks. Proc Natl Acad Sci U S A (2010) 1.77
The role of miR-18b in MDM2-p53 pathway signaling and melanoma progression. J Natl Cancer Inst (2013) 1.76
Spongiform neurodegeneration-associated E3 ligase Mahogunin ubiquitylates TSG101 and regulates endosomal trafficking. Mol Biol Cell (2007) 1.75
Inactivation of signal transducer and activator of transcription 3 in proopiomelanocortin (Pomc) neurons causes decreased pomc expression, mild obesity, and defects in compensatory refeeding. Endocrinology (2006) 1.75
Transcriptional regulation of agouti-related protein (Agrp) in transgenic mice. Endocrinology (2004) 1.73
MC1R variants increase risk of melanomas harboring BRAF mutations. J Invest Dermatol (2008) 1.72
A full-coverage, high-resolution human chromosome 22 genomic microarray for clinical and research applications. Hum Mol Genet (2002) 1.69
Genetics of dark skin in mice. Genes Dev (2003) 1.68
Ancestral components of admixed genomes in a Mexican cohort. PLoS Genet (2011) 1.67
Digital gene expression for non-model organisms. Genome Res (2011) 1.66
miRNA-205 suppresses melanoma cell proliferation and induces senescence via regulation of E2F1 protein. J Biol Chem (2011) 1.63
Cancer-associated mutations in chromatin remodeler hSNF5 promote chromosomal instability by compromising the mitotic checkpoint. Genes Dev (2005) 1.61
Interaction between alpha-melanocyte-stimulating hormone and corticotropin-releasing hormone in the regulation of feeding and hypothalamo-pituitary-adrenal responses. J Neurosci (2003) 1.61
Dominant role of the p110beta isoform of PI3K over p110alpha in energy homeostasis regulation by POMC and AgRP neurons. Cell Metab (2009) 1.59
A distinct subset of atypical Spitz tumors is characterized by BRAF mutation and loss of BAP1 expression. Am J Surg Pathol (2012) 1.57
Recurrent BRAF kinase fusions in melanocytic tumors offer an opportunity for targeted therapy. Pigment Cell Melanoma Res (2013) 1.56
Spongiform degeneration in mahoganoid mutant mice. Science (2003) 1.51
Acupuncture needling sensation: the neural correlates of deqi using fMRI. Brain Res (2009) 1.49
In vivo epinephrine-mediated regulation of gene expression in human skeletal muscle. J Clin Endocrinol Metab (2004) 1.49
Activation of Stat3 signaling in AgRP neurons promotes locomotor activity. Cell Metab (2008) 1.49
Genetic and morphologic features for melanoma classification. Pigment Cell Melanoma Res (2010) 1.47
BRAF mutations in cutaneous melanoma are independently associated with age, anatomic site of the primary tumor, and the degree of solar elastosis at the primary tumor site. Pigment Cell Melanoma Res (2011) 1.47
Metastatic melanoma in association with a giant congenital melanocytic nevus in an adult: controversial CGH findings. Am J Dermatopathol (2015) 1.45
Fierce: a new mouse deletion of Nr2e1; violent behaviour and ocular abnormalities are background-dependent. Behav Brain Res (2002) 1.44
Retracted Coordinated regulation of hepatic energy stores by leptin and hypothalamic agouti-related protein. J Neurosci (2013) 1.44
Mutation-driven drug development in melanoma. Curr Opin Oncol (2010) 1.43
The presence of polyomavirus in non-melanoma skin cancer in organ transplant recipients is rare. J Invest Dermatol (2008) 1.43
Structures of the agouti signaling protein. J Mol Biol (2005) 1.42
Hypothalamic neurodegeneration and adult-onset obesity in mice lacking the Ubb polyubiquitin gene. Proc Natl Acad Sci U S A (2008) 1.41
The future promise and the current reality of genetic prognostication in patients with uveal melanoma. Arch Ophthalmol (2008) 1.40
SOX2 amplification is a common event in squamous cell carcinomas of different organ sites. Hum Pathol (2011) 1.40
Bradykinin and histamine generation with generalized enhancement of microvascular permeability in neonates, infants, and children undergoing cardiopulmonary bypass surgery. Pediatr Crit Care Med (2003) 1.39
Hippi is essential for node cilia assembly and Sonic hedgehog signaling. Dev Biol (2006) 1.37
Human cytomegalovirus US28 found in glioblastoma promotes an invasive and angiogenic phenotype. Cancer Res (2011) 1.36
Dorsoventral patterning of the mouse coat by Tbx15. PLoS Biol (2004) 1.36
Caspase-7 expanded function and intrinsic expression level underlies strain-specific brain phenotype of caspase-3-null mice. J Neurosci (2004) 1.35
Linkage and segregation analysis of black and brindle coat color in domestic dogs. Genetics (2007) 1.32
Genetic analysis of Pten and Ink4a/Arf interactions in the suppression of tumorigenesis in mice. Proc Natl Acad Sci U S A (2002) 1.30
Dermoscopy of tungiasis. Arch Dermatol (2004) 1.29
The transcription factor encyclopedia. Genome Biol (2012) 1.28
Characterization of the dog Agouti gene and a nonagoutimutation in German Shepherd Dogs. Mamm Genome (2004) 1.28
Brain imaging of acupuncture: comparing superficial with deep needling. Neurosci Lett (2008) 1.28
Genetic architecture of skin and eye color in an African-European admixed population. PLoS Genet (2013) 1.28
Structural and molecular evolutionary analysis of Agouti and Agouti-related proteins. Chem Biol (2006) 1.27
Sunitinib therapy for melanoma patients with KIT mutations. Clin Cancer Res (2012) 1.23
Sporadic naturally occurring melanoma in dogs as a preclinical model for human melanoma. Pigment Cell Melanoma Res (2013) 1.20
Vemurafenib potently induces endoplasmic reticulum stress-mediated apoptosis in BRAFV600E melanoma cells. Sci Signal (2013) 1.19